Insiders · SMMT

SMMT insider transactions

Summit Therapeutics Inc. (SMMT) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for SMMT

• 4d
  Co-Chief Executive Officer Duggan Robert W bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 4d
  Co-Chief Executive Officer Zanganeh Mahkam bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 4d
  COO and CFO Soni Manmeet Singh bought $722,250 worth of shares (50,000 units at $14.45), increasing direct ownership by 2% to 3,123,603 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 147d
  SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 153d
  SEC Form 4 filed by Co-Chief Executive Officer Zanganeh Mahkam

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 153d
  SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 153d
  SEC Form 4 filed by Director Booth Robert F.

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 153d
  SEC Form 4 filed by Director Xia Yu

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 153d
  SEC Form 4 filed by Director Huber Jeff

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 153d
  SEC Form 4 filed by Director Ronaghi Mostafa

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 153d
  SEC Form 4 filed by Director Clark Kenneth A

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 153d
  SEC Form 4 filed by Director Cesano Alessandra

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 228d
  Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 228d
  Chief Accounting Officer Anand Bhaskar was granted 26,680 shares, increasing direct ownership by 20% to 159,751 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 228d
  COO and CFO Soni Manmeet Singh was granted 53,361 shares, increasing direct ownership by 2% to 3,073,603 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 228d
  Co-Chief Executive Officer Duggan Robert W bought $499,983 worth of shares (26,680 units at $18.74) and was granted 14,247,597 shares, increasing direct ownership by 3% to 570,073,879 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 228d
  Co-Chief Executive Officer Zanganeh Mahkam was granted 14,247,597 shares and bought $499,983 worth of shares (26,680 units at $18.74) (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 262d
  SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 270d
  Co-Chief Executive Officer Zanganeh Mahkam bought $5,984,756 worth of shares (338,394 units at $17.69) (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 270d
  Co-Chief Executive Officer Duggan Robert W bought $5,984,756 worth of shares (338,394 units at $17.69), increasing direct ownership by 0.06% to 556,093,090 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 371d
  Co-Chief Executive Officer Zanganeh Mahkam exercised 74,545 shares at a strike of $2.64 (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 371d
  Co-Chief Executive Officer Duggan Robert W exercised 74,545 shares at a strike of $2.64, increasing direct ownership by 0.01% to 555,754,696 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 403d
  SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 403d
  SEC Form 4 filed by COO and CFO Soni Manmeet Singh

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 403d
  SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 403d
  SEC Form 4 filed by Co-Chief Executive Officer Zanganeh Mahkam

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 425d
  Co-Chief Executive Officer Zanganeh Mahkam exercised 3,985,055 in-the-money shares at a strike of $1.58 (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 425d
  Co-Chief Executive Officer Duggan Robert W exercised 3,985,055 in-the-money shares at a strike of $1.58, increasing direct ownership by 0.72% to 555,680,151 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 510d
  SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 518d
  SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 518d
  SEC Form 4 filed by Co-Chief Executive Officer Zanganeh Mahkam

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 518d
  SEC Form 4 filed by Director Huber Jeff

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 518d
  SEC Form 4 filed by Director Xia Yu

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 518d
  SEC Form 4 filed by Director Cesano Alessandra

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 518d
  SEC Form 4 filed by Director Ronaghi Mostafa

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 518d
  SEC Form 4 filed by Director Clark Kenneth A

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 518d
  SEC Form 4 filed by Director Booth Robert F.

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 601d
  SEC Form 4 filed by Director Clark Kenneth A

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 613d
  Co-Chief Executive Officer Zanganeh Mahkam exercised 315,681 in-the-money shares at a strike of $1.58 (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 633d
  Co-Chief Executive Officer Zanganeh Mahkam was granted 44,052 shares (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 633d
  Co-Chief Executive Officer Duggan Robert W was granted 3,325,991 shares, increasing direct ownership by 0.61% to 551,695,096 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 633d
  Director Huber Jeff was granted 44,052 shares (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 633d
  COO and CFO Soni Manmeet Singh was granted 44,052 shares, increasing direct ownership by 1% to 3,020,242 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 633d
  Chief Accounting Officer Anand Bhaskar was granted 22,026 shares, increasing direct ownership by 20% to 131,426 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 654d
  SEC Form 4 filed by COO and CFO Soni Manmeet Singh

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 654d
  SEC Form 4 filed by Chief Executive Officer Zanganeh Mahkam

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 711d
  SEC Form 4 filed by Director Huber Jeff

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 711d
  New insider Huber Jeff claimed ownership of 6,000 shares (SEC Form 3)

  3 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 784d
  SEC Form 4 filed by Ronaghi Mostafa

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 784d
  SEC Form 3 filed by new insider Ronaghi Mostafa

  3 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 795d
  SEC Form 4 filed by Soni Manmeet Singh

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 795d
  SEC Form 4 filed by Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 795d
  New insider Anand Bhaskar claimed ownership of 109,400 shares (SEC Form 3)

  3 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 803d
  Zanganeh Mahkam bought $411,094 worth of shares (110,321 units at $3.73), increasing direct ownership by 5% to 520,814 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 803d
  Dhingra Ankur bought $375,000 worth of shares (100,000 units at $3.75) (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 845d
  SEC Form 5 filed by Xia Yu

  5 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 886d
  SEC Form 4 filed by Cesano Alessandra

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 886d
  SEC Form 4 filed by Booth Robert F.

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 886d
  SEC Form 4 filed by Clark Kenneth A

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 886d
  SEC Form 4 filed by Mahatme Ujwala

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)